These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2788028)

  • 1. Decreased natural killer (NK) activity in patients with myeloproliferative disorders.
    Froom P; Aghai E; Kinarty A; Lahat N
    Cancer; 1989 Sep; 64(5):1038-40. PubMed ID: 2788028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
    Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
    Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of natural killer cell activity in the pathogenesis of chronic myeloproliferative diseases].
    Guseva SA
    Lik Sprava; 1993 Jul; (8):70-3. PubMed ID: 8079482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic dysfunction in the myeloproliferative disorders.
    DiBella NJ; Brown GL
    Cancer; 1978 Jul; 42(1):149-58. PubMed ID: 276412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced natural killer activity in patients with Fanconi's anemia and in family members.
    Froom P; Aghai E; Dobinsky JB; Quitt M; Lahat N
    Leuk Res; 1987; 11(2):197-9. PubMed ID: 3493394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin.
    Mori S; Jewett A; Cavalcanti M; Murakami-Mori K; Nakamura S; Bonavida B
    Int J Oncol; 1998 May; 12(5):1165-70. PubMed ID: 9538144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines.
    Alvarado CS; Findley HW; Chan WC; Hnath RS; Abdel-Mageed A; Pais RC; Kutner MH; Ragab AH
    Cancer; 1989 Jan; 63(1):83-9. PubMed ID: 2783377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood and neoplastic diseases. Myeloproliferative disorders.
    Lewis SM; Szur L
    Br Med J; 1974 Nov; 4(5941):399-402. PubMed ID: 4425895
    [No Abstract]   [Full Text] [Related]  

  • 10. [The treatment of myeloproliferative syndromes].
    Maurice P
    Schweiz Med Wochenschr; 1975 Oct; 105(40):1269-74. PubMed ID: 1061995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes.
    Struyf NJ; Snoeck HW; Bridts CH; De Clerck LS; Stevens WJ
    Ann Rheum Dis; 1990 Sep; 49(9):690-3. PubMed ID: 1700674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.
    Riley CH; Jensen MK; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM
    Blood; 2011 Aug; 118(8):2170-3. PubMed ID: 21708889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen.
    Brooks CG; Holscher M; Urdal D
    J Immunol; 1985 Aug; 135(2):1145-52. PubMed ID: 2409140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.
    Handa K; Suzuki R; Matsui H; Shimizu Y; Kumagai K
    J Immunol; 1983 Feb; 130(2):988-92. PubMed ID: 6294182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer cell function and modulation by alpha IFN and IL2 in AIDS patients and prodromal subjects.
    Lew F; Tsang P; Solomon S; Selikoff IJ; Bekesi JG
    J Clin Lab Immunol; 1984 Jul; 14(3):115-21. PubMed ID: 6237206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of in vitro porcine natural killer cell activity by recombinant interleukin-1 alpha, interleukin-2 and interleukin-4.
    Knoblock KF; Canning PC
    Immunology; 1992 Jun; 76(2):299-304. PubMed ID: 1634252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
    Frey JR; Kamber M; Peck R
    Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of interferon-alpha (MOR-22) on human NK cell activity].
    Yanagihara Y; Tochizawa S; Ishii K; Hirai Y
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):342-8. PubMed ID: 3947110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
    Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
    Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.